AH
PRQR icon

Andreas Halvorsen’s ProQR Therapeutics PRQR Stock Holding History

Andreas Halvorsen’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-581,668
Closed -$5.05M – 77
2015
Q4 		$5.05M Buy
581,668
+5,036
+0.9% +$57.9K 0.02% 63
2015
Q3 		$8.4M Sell
576,632
-18,675
-3% -$313K 0.03% 59
2015
Q2 		$9.92M Buy
595,307
+186,899
+46% +$3.52M 0.04% 55
2015
Q1 		$8.94M Buy
+408,408
New +$8.43M 0.03% 57

Other funds holding PRQR

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

Andreas Halvorsen's PRQR Position: Q1 2016 in Review

Andreas Halvorsen sold out of ProQR Therapeutics (PRQR) in Q1 2016, closing a stake of 581,668 shares — an estimated $5.05M sold.

Andreas Halvorsen first reported a position in PRQR in Q1 2015 and held it in 4 quarters. The position peaked at $9.92M in Q2 2015. 29 funds tracked by Wall St. Rank hold PRQR as of Q1 2016.

  • Andreas Halvorsen reported no remaining ProQR Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Andreas Halvorsen sold 581,668 ProQR Therapeutics shares in Q1 2016, an estimated $5.05M.
  • Andreas Halvorsen first reported a position in ProQR Therapeutics in Q1 2015 and held it in 4 quarters.
  • Andreas Halvorsen's ProQR Therapeutics position peaked at $9.92M in Q2 2015.
  • 29 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2016.

Based on Viking Global Investors's 13F filing for Q1 2016, filed 16 May 2016.